Associations between thiazide diuretic use and calciuria in patients with hypoparathyroidism: an observational cohort study

PURPOSE: The standard medical management of chronic hypoparathyroidism includes supplementation with calcium, vitamin D3 (cholecalciferol) and active 1,25-dihydroxyvitamin D (calcitriol), however in severe cases​ this treatment can be limited by hypercalciuria. In daily clinical practice, thiazide diuretics may be administered to reduce calciuria, but only few data are available on the effects of thiazide use in hypoparathyroidism. The objective of this study was to investigate biochemical and clinical changes in patients receiving thiazide diuretics for the treatment of hypoparathyroidism. METHODS: In this retrospective observational study, we investigated patients receiving thiazide diuretics for the treatment of hypoparathyroidism at our endocrine outpatient clinic. Clinical and biochemical parameters were collected at the time of first presentation, before the initiation of thiazide treatment, and at the time of last check-up. RESULTS: Out cohort includes 145 patients with hypoparathyroidism. 34 patients (23.4%) received thiazides due to higher urinary calcium excretion (UCaE). The subcohort treated with thiazides was monitored for 4.6 years. Under a median dose of 12.5 mg hydrochlorothiazide, UCaE significantly decreased from 9.9 mmol/24 h before hydrochlorothiazide to 6.0 mmol/24 h (p < 0.001) at the last observational visit, corresponding to a mean UCaE reduction by 32.4% (95% CI 19.3-45.5). Serum calcium, magnesium, kidney function and blood pressure remained stable. Thiazide treatment was discontinued in 12 patients (26%), with electrolyte disturbances and vertigo as the most common causes. CONCLUSION: These data indicate that the add-on of hydrochlorothiazide to conventional therapy in patients with hypoparathyroidism significantly lowers calciuria, but does not impact serum calcium, magnesium or kidney function.

Authors

Institutions

Publication Details

Journal
Endocrine
Published
2026-11-16
DOI
https://doi.org/10.1007/s12020-026-04842-x
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Associations between thiazide diuretic use and calciuria in patients with hypoparathyroidism: an observational cohort study

Gabriele Grimm, Greisa Vila, Christian Scheuba, Alexandra Kautzky‐Willer et al.
Endocrine
Parathyroid Disorders and Treatments
article

Associations between thiazide diuretic use and calciuria in patients with hypoparathyroidism: an observational cohort study

Gabriele Grimm, Greisa Vila, Christian Scheuba, Alexandra Kautzky‐Willer, Marie Helene Schernthaner-Reiter, Christine Wagenlechner, A Luger, C Looser, Philipp Riss, Anna Elisabeth Nagel
article en

Abstract

PURPOSE: The standard medical management of chronic hypoparathyroidism includes supplementation with calcium, vitamin D3 (cholecalciferol) and active 1,25-dihydroxyvitamin D (calcitriol), however in severe cases​ this treatment can be limited by hypercalciuria. In daily clinical practice, thiazide diuretics may be administered to reduce calciuria, but only few data are available on the effects of thiazide use in hypoparathyroidism. The objective of this study was to investigate biochemical and clinical changes in patients receiving thiazide diuretics for the treatment of hypoparathyroidism. METHODS: In this retrospective observational study, we investigated patients receiving thiazide diuretics for the treatment of hypoparathyroidism at our endocrine outpatient clinic. Clinical and biochemical parameters were collected at the time of first presentation, before the initiation of thiazide treatment, and at the time of last check-up. RESULTS: Out cohort includes 145 patients with hypoparathyroidism. 34 patients (23.4%) received thiazides due to higher urinary calcium excretion (UCaE). The subcohort treated with thiazides was monitored for 4.6 years. Under a median dose of 12.5 mg hydrochlorothiazide, UCaE significantly decreased from 9.9 mmol/24 h before hydrochlorothiazide to 6.0 mmol/24 h (p < 0.001) at the last observational visit, corresponding to a mean UCaE reduction by 32.4% (95% CI 19.3-45.5). Serum calcium, magnesium, kidney function and blood pressure remained stable. Thiazide treatment was discontinued in 12 patients (26%), with electrolyte disturbances and vertigo as the most common causes. CONCLUSION: These data indicate that the add-on of hydrochlorothiazide to conventional therapy in patients with hypoparathyroidism significantly lowers calciuria, but does not impact serum calcium, magnesium or kidney function.

EndocrineVol. 91(1)
Medical University of Vienna (AT)
Medizinische Universität Wien
Good health and well-being
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon